

Updated June 2014

MarketVIEW: Chikungunya virus vaccines (CAT: VAMV005)

Product Name:	Chikungunya virus vaccines
Description	Global vaccine commercial opportunity assessment
Contents	Executive presentation + forecast model
Therapeutic area	Novel vaccines
Publication date	June 2014
Catalogue No	VAMV005

Background

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases the virus can cause recurrent disease, neurological complications and severe neonatal disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recently outbreaks have occurred in previously CHIK free countries, including China, Papua New Guinea, Laos, New Caledonia and Bhutan. The first documented outbreak of CHIK in the Americas occurred in December 2012: as of April 2014, more than 40,000 probable and confirmed cases were reported. Because there is no specific treatment for CHIK infection many institutions have considered the prospect for a prophylactic vaccine.

This expert report comprises of two deliverables 1) A commercial summary presentation and 2) An Excel-based commercial forecast model which details potential demand (doses) and gross sales revenues (\$USD) in all potential target markets for a prophylactic Chikungunya vaccine. For each target market characteristics and model assumptions are clearly presented along with relevant cases studies of other vaccines currently licensed for travelling populations and private markets of SE Asia. The report has been structured to provide expert guidance as to the commercial viability of a CHIK vaccine.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Chikungunya virus. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research on endemic/travel vaccines **VacZine Analytics** has also been utilised.

PRODUCT CONTENTS:

Updated June 2014 (CAT No: VAMV005)

This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Authors Note
Executive summary
CHIK vaccines: global value per segment (\$m) to 2035
CHIK vaccines: global volume per segment (doses) to 2035
Travel market: by region of departure (value/volume) to 2035
Endemic markets: by country/region (value/volume) to 2035
Forecast comparisons: June 2009 vs. June 2014
Chikungunya virus: commercial model assumptions
Potential markets for a CHIK vaccine
Potential markets for a CHIK vaccine: endemic (private)
Potential markets for a CHIK vaccine: travellers
Potential markets for a CHIK vaccine: military
Potential markets for a CHIK vaccine: Western stockpile
Chikungunya virus: background
Clinical features
CHIK: characteristics of an outbreak (2005-06)
Treatment and prevention
Reporting and surveillance
Epidemiology
CHIK: comparison to other vector borne diseases
Epidemiology: countries reporting CHIK
Epidemiology: the Americas
Chikungunya virus: future dynamics
Future market trends: drivers & resistors
Future market trends: outbreak risks
Future market trends: vector distribution (EU)
Future market trends: LATAM
Future market trends: global outbreak risk areas
Future market trends: vaccines
Future market trends: cyclical factors
Future market trends: focus on India
Chikungunya virus: vaccine R&D pipeline
R&D pipeline: summary table
References/Bibliography
About **VacZine Analytics**

Continued.....

Disclaimer

PAGES: >50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Charts – volume/value
Value summary (All)
Volume summary (All)
Traveller markets
US – travellers
EU – travellers
Japan – travellers
Endemic markets (private)
Endemic – private (Africa)
Endemic – private (Other Asia)
Endemic – private (India)
Endemic – private (China)
Endemic – private (LATAM)
Source material
CHIK countries (CDC)
Traveller database (All)
Traveller database (US)
Traveller database (Japan)
Traveller database (EU)
Urban populations – (Africa)
Urban populations – (SE Asia)
Urban populations – (India)
CHIK countries
Back page

Worksheets = 25

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - **USD \$7995.00/ GBP £4845.00**[#] (Region license)*
- PRESENTATION OR MODEL ONLY - **USD \$3995.00** (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

Indicative rate only. Prevailing rate applied to date of transaction.

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

Bibliography

1. Chopra A et al. Acute Chikungunya and persistent musculoskeletal pain following the 2006 Indian epidemic. *Epidemiol Infect.* 2012 May;140(5):842-50.
2. Kularatne SA et al. Epidemiology, clinical manifestations, and long-term outcomes of a major outbreak of chikungunya in a hamlet in Sri Lanka, in 2007. *J Trop Med.* 2012;2012:639178.
3. Kosasih H et al. Evidence for endemic chikungunya virus infections in Bandung, Indonesia. *PLoS Negl Trop Dis.* 2013 Oct 24;7(10):e2483
4. Josseran L et al. Chikungunya disease outbreak, Réunion Island. *Emerg Infect Dis.* 2006 Dec;12(12):1994-5.
5. Ravi V. Re-emergence of Chikungunya virus in India. *Indian J Med Microbiol* 2006; 24: 83-4.
6. Qiaoli Z et al. Maiden outbreak of chikungunya in Dongguan city, Guangdong province, China: epidemiological characteristics. *PLoS One.* 2012;7(8):e42830.
7. Horwood PF et al. Outbreak of chikungunya virus infection, Vanimo, Papua New Guinea. *Emerg Infect Dis.* 2013;19(9):1535-8.
8. SoulaPHY C et al. Emergence of chikungunya in Moonlapamok and Khong Districts. *Western Pac Surveill Response J.* 2013 Mar 18;4(1):46-50.
9. European Centre for Disease Prevention and Control. Monitoring current threats: ECDC Communicable Disease Threats Report, week 20/2014
10. Chikungunya virus. US Centers For Disease Control and Prevention (CDC). Geographic Distribution. Available at: <http://www.cdc.gov/chikungunya/geo/index.html>. Accessed: May 2014
11. Tomasello D et al. Chikungunya and dengue autochthonous cases in Europe, 2007-2012. *Travel Med Infect Dis.* 2013 Sep-Oct;11(5):274-84.
12. Ruiz-Moreno D et al. Modeling dynamic introduction of Chikungunya virus in the United States. *PLoS Negl Trop Dis.* 2012;6(11):e1918.
13. Gibney KB et al. Chikungunya fever in the United States: a fifteen year review of cases. *Clin Infect Dis.* 2011 Mar 1;52(5):e121-6.
14. Mizuno Y et al. [First case of chikungunya fever in Japan with persistent arthralgia] *Kansenshogaku Zasshi.* 2007 Sep;81(5):600-1.
15. Cha GW et al. Travel-Associated Chikungunya Cases in South Korea during 2009-2010. *Osong Public Health Res Perspect.* 2013 Jun;4(3):170-5.
16. European Centre for Disease Prevention and Control. Mosquito maps. Available at: http://www.ecdc.europa.eu/en/healthtopics/vectors/vector-maps/Pages/VBORNET_maps.aspx. Accessed: June 2014.
17. World Health Organisation. Available at: www.who.int. Accessed May 2014
18. Directorate Of National Vector Borne Disease Control Programme. Chikungunya Fever Situation in the Country during 2006. Available at: <http://www.nvbdc.gov.in/>. Accessed: May 2009
19. Muniaraj M. Fading chikungunya fever from India: beginning of the end of another episode? *Indian J Med Res.* 2014 Mar;139(3):468-70.
20. Hoke CH Jr et al. US Military contributions to the global response to pandemic chikungunya. *Vaccine.* 2012 Oct 19;30(47):6713-20.
21. Edelman R et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD 218. *Am J Trop Med Hyg* 2000; 62 : 681-5.
22. Brandler S et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. *Vaccine.* 2013 Aug 12;31(36):3718-25
23. Chu H et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. *Vaccine.* 2013 Jul 18;31(33):3353-60.
24. Tretyakova I et al. DNA Vaccine Initiates Replication of Live Attenuated Chikungunya Virus In Vitro and Elicits Protective Immune Response in Mice. *J Infect Dis.* 2014 Mar 31.
25. Weaver SC et al. Chikungunya virus and prospects for a vaccine. *Expert Rev Vaccines.* 2012 Sep;11(9):1087-101.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009